Upstream Bio (NASDAQ:UPB) Hits New 52-Week Low – Time to Sell?

Upstream Bio, Inc. (NASDAQ:UPB)’s share price hit a new 52-week low during mid-day trading on Saturday . The company traded as low as $10.24 and last traded at $10.39, with a volume of 206423 shares traded. The stock had previously closed at $10.77.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Piper Sandler assumed coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They set an “overweight” rating and a $75.00 price objective for the company. William Blair started coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. began coverage on Upstream Bio in a research note on Tuesday, November 5th. They set an “overweight” rating and a $38.00 target price on the stock. Finally, TD Cowen initiated coverage on Upstream Bio in a research note on Tuesday, November 5th. They issued a “buy” rating for the company.

Upstream Bio Trading Down 3.5 %

The company has a 50 day moving average of $17.55.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Thursday, November 7th. The company reported ($6.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($6.38). The business had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.83 million. As a group, equities analysts expect that Upstream Bio, Inc. will post -4.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Upstream Bio stock. Moody Aldrich Partners LLC acquired a new position in Upstream Bio, Inc. (NASDAQ:UPB) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 74,773 shares of the company’s stock, valued at approximately $1,229,000. Moody Aldrich Partners LLC owned 0.14% of Upstream Bio as of its most recent SEC filing.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.